Figure 5

Probability estimates of progression-free survival time of patients with metastatic renal cell carcinoma treated with nivolumab (a) (n = 20) and stratification by tumour grade (b). Also shown are the probability estimates of cancer-specific survival time of the same patients (c) (n = 20) and stratification by tumour grade (d). Statistical analysis was performed by log-rank test.